Assessment of comedogenicity and skin reactions to siodil acne treatment products: A preliminary clinical trial

Background: Acne vulgaris is a common dermatological condition influenced by factors such as pore blockage, excessive sebum production, and inflammation. This study evaluates the comedogenicity, skin tolerability, and functional benefits of Siodil acne treatment products, including Sebi Gel, Sebi Serum, Sebi Cleanser, and ATO Gel. Methods: A total of 26 participants aged 18–40 years underwent a 28-day open-label trial to assess the impact of Siodil products on pore blockage, skin hydration, and acne reduction. Comedogenicity was scored using a standardized acne grading scale, and patch tests were conducted to evaluate erythema and edema. Participant satisfaction and product tolerability were also assessed. Results: All products demonstrated significant improvements in skin hydration, with ATO Gel showing the highest improvement (32.47%), followed by Sebi Gel (30.56%). Acne breakout reduction was highest for Sebi Cleanser (85%), while Sebi Serum showed the greatest whitehead/blackhead reduction (76.92%). Patch tests revealed no occurrences of erythema or edema at 24 and 48 hours. Participant feedback indicated high satisfaction, with Sebi Gel receiving the highest satisfaction rating (90%). Conclusion: Siodil acne treatment products effectively reduce acne-related outcomes while improving skin hydration and demonstrating excellent tolerability. These findings suggest Siodil products are safe and effective for managing acne-prone skin, though further research is warranted to confirm these results in larger populations.